Uterine Fibroids (Leiomyoma)MyoMwaNCT07780019
Microwave Ablation of Uterine Fibroids
An observational study of Uterine Fibroids (Leiomyoma), run by Turku University Hospital at 1 site in Finland.
Trial summary
This prospective observational study aims to evaluate the effectiveness and acceptability of percutaneous or vaginal ultrasound guided microwave ablation for the treatment or symptomatic uterine fibroids. We will include 100 women. Read more about this study
- Who is it for?
- Ages 18 to 56 years, women only
- Conditions the study is for
- Uterine Fibroids (Leiomyoma)
- What is being tested?
- microwave ablation
- Type of treatment
- Surgery or procedure
- How many people
- 100 participants
- Where
- 1 siteFinland
- Study dates
- 1 May 2026to Dec 2034
- How long will I take part?
- 12 Months
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 56 years
- Women only
- No healthy volunteers
- Adult
Study population: patients undergoing mwa for symptomatic uterine fibroids will be recruited for this study
Who may be able to join
- symptomatic fibroids
- premenopausal status
- acceptable risks for general anestesia or sedation
- willing to undergo mwa treatment and participate in the study
Who cannot join
- postmenopausal status
- bleeding disorder with increased risk of bleeding
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prospective Observational Study of Microwave Ablation of Uterine Fibroids (MyoMwa)
This prospective observational study aims to evaluate the effectiveness and acceptability of percutaneous or vaginal ultrasound guided microwave ablation for the treatment or symptomatic uterine fibroids. We will include 100 women.
- Conditions
- Uterine Fibroids (Leiomyoma)
- Being tested
- microwave ablation
- Keywords
- microwave ablation
- Medical subject headings
- Leiomyoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
microwave ablationProcedure or surgery
ultrasound guided percutaneus microwave ablation
| Study group | Role | What they receive |
|---|---|---|
| patients with symptomatic uterine fibroids | Patients with symptomatic uterine fibroids, who will undergo microwave ablation of fibroids as a clinical treatment are recruited in this study. Receives: Procedure: microwave ablation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Symptom severity of uterine fibroids and quality of life
Score of validated form Uterine Fibroid symptom - Quality of life questinnaire. minimum 0, maximum 100 where higher scores indicate higher symptom severity
Measured: 12 months
suitability of mwa for general fibroid population
objective and subjective outcome of mwa in different fibroid types, sizes and locations
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2026
- Study start1 May 2026
- Primary completionDec 2031 (estimated)
- Study completionDec 2034 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Uterine Fibroids (Leiomyoma)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Turku University Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Kirsi Joronen, Turku University Hospital
- Investigators
- Kirsi Joronen, Principal investigator, Turku University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07780019
- Sponsor's protocol ID
- T2026/43353
- Acronym
- MyoMwa
- Status last verified
- Aug 2026
- First submitted
- 12 Aug 2026
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No